Showing results (1831-1840 of 2,014) with videos related to

Sort By:
Pageof 202
Zhonghua Xue Ye Xue Za Zhi = Zhonghua Xueyexue Zazhi|April 16, 2026
[Treatment practice and outcomes in 125 patients with autoimmune hemolytic anemia: a single-center retrospective analysis]F Yang, R N Li, L L Zhang, et al.
Zhonghua Wai Ke Za Zhi [Chinese Journal of Surgery]|June 8, 2021
[The Chinese guidelines for the diagnosis and treatment of pancreatic neuroendocrine neoplasms (2020)]W M Wu, J Chen, C M Bai, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|February 23, 2026
Identifying patients with high risk stage I NSCLC using tumor-informed plasma ctDNAJamie Feng, Sameena Khan, Thomas Waddell, et al.
ESMO Open|June 10, 2025
Pan-Asia adapted ESMO Clinical Practice Guideline for the management of patients with newly diagnosed and relapsed epithelial ovarian cancerS Nag, I Ray Coquard, S Gupta, et al.
European Review for Medical and Pharmacological Sciences|January 4, 2015
The prevalence of Parkinson's disease continues to rise after 80 years of age: a cross-sectional study of Chinese veteransY-M Zou, J-P Tan, N Li, et al.
World Journal of Surgery|March 7, 2013
Adjuvant hepatic intra-arterial iodine-131-lipiodol following curative resection of hepatocellular carcinoma: a prospective randomized trialA Y F Chung, L L P J Ooi, D Machin, et al.
BMC Medicine|July 12, 2015
Intracoronary infusion of Wharton's jelly-derived mesenchymal stem cells in acute myocardial infarction: double-blind, randomized controlled trialLian R Gao, Yu Chen, Ning K Zhang, et al.
Zhonghua Liu Xing Bing Xue Za Zhi = Zhonghua Liuxingbingxue Zazhi|March 2, 2018
[Preference on screening frequency and willingness-to-pay for multiple-cancer packaging screening programs in urban populations in China]J Zhu, H Y Huang, A Y Mao, et al.
Zhonghua Liu Xing Bing Xue Za Zhi = Zhonghua Liuxingbingxue Zazhi|March 2, 2018
[Willingness and preferences of actual service suppliers regarding cancer screening programs: a multi-center survey in urban China]J F Shi, A Y Mao, Z X Sun, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|May 16, 2026
Preclinical characterization and phase 1 results of TQB2102, a first-in-class HER2 biparatopic antibody-drug conjugate, in patients with advanced solid tumorsD Y Ruan, S Y Lin, J J Huang, et al.
Pageof 202